Biopas and moksha8 in strategic alliance to commercialize drugs across Latin America

16 June 2014

Panamanian drugmaker Biopas and Brazil-based moksha8 have entered into a strategic alliance combining strong capabilities, regional presence and product pipelines.

The alliance immediately creates a unique regional provider of high quality, specialty pharmaceutical products across one of the world's fastest growing, high value markets. Biopas and moksha8 will collaborate on both existing and future corporate development partnerships.

The Latin America retail pharmaceutical market is estimated by IMS at $68 billion in 2013, expanding at a 12% compound annual growth rate (CAGR) to over $110 billion by 2017. Brazil (pictured) is expected to be the fourth largest pharmaceutical market in the world by 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK